Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18031544 | 1.00 | SHBG (0.41) | SHBGDEGS1TSHRIDH1 | |
| SCHEMBL11945787 | 1.00 | SHBG (0.41) | SHBGDEGS1TSHRIDH1 | |
| SCHEMBL4546673 | 0.86 | — | — | |
| SCHEMBL74849 | 0.86 | DEGS1 (0.36) | DEGS1 | |
| SCHEMBL10121187 | 0.86 | DEGS1 (0.36) | DEGS1 | |
| SCHEMBL8969464 | 0.85 | LMNA (0.36) | SHBGDEGS1 | |
| Ammonia Solution, Strong SCHEMBL8076876 | 0.83 | — | — | |
| SCHEMBL9150285 | 0.82 | SHBG (0.34) | SHBGTSHR | |
| SCHEMBL19945247 | 0.80 | SHBG (0.33) | SHBG | |
| SCHEMBL19773990 | 0.78 | DEGS1 (0.33) | DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| WO-2017091600-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
| EP-2400846-B1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | SHBG 3829/4885DEGS1 3582/4885TSHR 4729/4885 |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SHBG 4504/4885DEGS1 4345/4885TSHR 1652/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SHBG 4504/4885DEGS1 4345/4885TSHR 1652/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SHBG 4504/4885DEGS1 4345/4885TSHR 1652/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | SHBG 4504/4885DEGS1 4345/4885TSHR 1652/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | SHBG 4504/4885DEGS1 4345/4885TSHR 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.